FY2025 EPS Estimates for MetaVia Boosted by Zacks Small Cap

MetaVia Inc. (NASDAQ:MTVA) – Equities researchers at Zacks Small Cap increased their FY2025 earnings per share estimates for shares of MetaVia in a report released on Monday, November 10th. Zacks Small Cap analyst D. Bautz now expects that the company will earn ($0.90) per share for the year, up from their previous forecast of ($1.12). The consensus estimate for MetaVia’s current full-year earnings is ($3.90) per share. Zacks Small Cap also issued estimates for MetaVia’s Q4 2025 earnings at ($0.21) EPS, FY2026 earnings at ($0.93) EPS and FY2027 earnings at ($0.87) EPS.

Several other equities research analysts have also recently issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of MetaVia in a report on Wednesday, October 8th. HC Wainwright initiated coverage on MetaVia in a research note on Thursday, September 4th. They issued a “buy” rating and a $12.00 price target on the stock. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $7.50.

MetaVia Stock Down 7.9%

MTVA stock opened at $0.71 on Wednesday. MetaVia has a 52 week low of $0.56 and a 52 week high of $2.75. The firm has a 50-day simple moving average of $0.96 and a 200-day simple moving average of $0.78. The stock has a market capitalization of $17.09 million, a P/E ratio of -0.60 and a beta of 0.37.

MetaVia (NASDAQ:MTVA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.12.

Institutional Investors Weigh In On MetaVia

A hedge fund recently raised its stake in MetaVia stock. SG Americas Securities LLC increased its holdings in MetaVia Inc. (NASDAQ:MTVA) by 44.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 60,386 shares of the company’s stock after acquiring an additional 18,506 shares during the period. SG Americas Securities LLC owned approximately 0.25% of MetaVia worth $57,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 1.37% of the company’s stock.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.